Intraperitoneal gene therapy with adenoviral-mediated p53 tumor suppressor gene for ovarian cancer model in nude mouse

Cancer Gene Therapy

Volumn 6, Issue 2, 1999, Pages 172-178

  Kim, Jhingook ^a   Hwang, Eun Sung ^a   Kim, Jong Sik ^a   You, Eun Hwoi ^a   Lee, Sook Hyun ^a   Lee, Je Ho ^a,b  

^a Samsung Medical Center   (South Korea)

^b Sungkyunkwan University   (South Korea)

Author keywords

Ovarian cancer; p53 gene therapy; Peritoneal tumor

Indexed keywords

BETA GALACTOSIDASE; CDKN1A PROTEIN, HUMAN; CDKN1A PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE;

ADENOVIRUS; ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CELL CULTURE; COMPARATIVE STUDY; DOSE RESPONSE; FEMALE; GENE THERAPY; GENETIC TRANSDUCTION; GENETICS; HUMAN; IMMUNOBLOTTING; INFUSION; METABOLISM; METASTASIS; METHODOLOGY; MOUSE; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; TIME; TUMOR SUPPRESSOR GENE;

ADENOVIRIDAE; ANIMALS; BETA-GALACTOSIDASE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE THERAPY; GENES, P53; HUMANS; IMMUNOBLOTTING; INFUSIONS, PARENTERAL; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; TIME FACTORS; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0033093678     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700006     Document Type: Article

References (19)

1. Lee SI. Annual Report of Cancer Registry Programme in the Republic of Korea, Jan. 1, 1994-Dec. 31, 1994. Seoul, Korea: Ministry of Health and Welfare; 1996:3-33.
2. Parkin DM, Laara E, Muir CS. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer. 1988;41:184-197.
3. McGarrity K. Primary carcinoma of ovary. Aust NZ J Obstet Gynecol. 1971;11:103-116.
4. Zhang WW, Fang X, Mazur W, French BA, Georges R, Roth JA. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther. 1994;1:5-13.
5. Wills KN, Maneval DC, Menzel P, et al. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther. 1994;5:1079-1088.
6. Liu TJ, El-Naggar AK, McDonnell TJ, et al. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res. 1995;55:3117-3122.
7. Eastern JA, Hall SJ, Sehgal I, et al. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res. 1995;55:5151-5155.
8. Bosari S, Viale G, Radaelli U, Bossi P, Bonoldi E, Coggi G. P53 accumulation in ovarian carcinomas and its prognostic implications. Hum Pathol. 1993;24:1175-1179.
9. Lee JH, Kang YS, Park SY, et al. p53 mutation in epithelial ovarian cancer and borderline ovarian tumor. Cancer Genet Cytogenet. 1995;85:43-50.
10. Hwang ES, Kim J, Kim JS, et al. The effects of the adenoviral-mediated wild-type p53 delivery in human epithelial ovarian cancer cell lines in vitro and in vivo. Int J Gynecol Cancer. 1998;8:27-36.
11. McGrory WJ, Bautista DS, Graham FL. A simple technique for the rescue of early region 1 mutation into infectious human adenovirus type 5. Virology. 1988;163: 614-617.
12. Davidson BL, Allen ED, Kozarsky KF, Wilson JM, Roessler BJ. A model system for in vivo gene transfer into the CNS using an adenoviral vector. Nat Genet. 1993;3: 219-223.
13. Tong XW, Block A, Chen SH, et al. In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration. Gynecol Oncol. 1996;61:175-179.
14. Rosenfeld ME, Wang M, Siegal GP, et al. Adenoviral-mediated delivery of herpes simplex virus thymidine kinase results in tumor reduction and prolonged survival in a SCID mouse model of human ovarian carcinoma. J Mol Med. 1996;74:455-462.
15. Smythe WR, Hwang HC, Elshami AA, Amin KM, Albelda S, Kaiser LR. Differential sensitivity of thoracic malignant tumors to adenovirus-mediated drug sensitization gene therapy. J Thorac Cardiovasc Surg. 1995;109:626-631.
16. Zhang WW, Alemany R, Wang J, Koch PE, Ordonez N, Roth JA. Safety evaluation of Ad5CMV-p53 in vitro and in vivo. Hum Gene Ther. 1995;6:155-164.
17. Heintz APM, Hacker NF, Berek JS, et al. Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet Gynecol. 1986;67:783-788.
18. Piver MS, Baker T. The potential for optimal (<2 cm) cytoreductive surgery in advanced ovarian carcinoma at a tertiary medical center: a prospective study. Gynecol Oncol. 1986;24:1-8.
19. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 1975;42:101-104.